Artificial intelligence can now look at a photograph of the back of your eye and spit out a number labeled as your age. Sometimes that number is close to your chronological age; sometimes it is years off, and headlines have been quick to suggest that a gap between the two reveals how fast you are really aging. A new review published in the journal Biogerontology by Henry Bair of Wills Eye Hospital in Philadelphia argues that this seductive simplicity hides a thicket of technical and conceptual problems. The review, which synthesizes evidence from fundus photography, optical coherence tomography, ocular fluids, systemic omics, and multimodal models, proposes a framework for interpreting what these ocular age estimates actually measure, and it warns that a raw age gap is not an aging rate, not a prognostic marker, and not automatically a clinically actionable test.
The eye is, in many respects, an ideal organ for aging research. It is paired, which allows within-person comparisons; it can be imaged repeatedly and non-invasively over decades; it can be treated locally with injections, lasers, and surgery; and its function can be quantified with extraordinary precision, from visual acuity to contrast sensitivity to dark adaptation. This tractability has fueled an explosion of models that estimate biological age from retinal images and other ocular data. Deep learning applied to retinal photographs has been reported to predict biological age and stratify morbidity and mortality risk. Multimodal retinal aging clocks built on optical coherence tomography and fundus imaging have been proposed for systemic health assessment. Liquid-biopsy proteomics of ocular fluids, combined with machine learning, has been used to identify cellular drivers of eye aging in vivo. Each of these approaches produces a number expressed in years, but the review emphasizes that the familiar unit conceals fundamental differences in what was measured and what the model was built to predict.
To untangle these differences, Bair proposes an eye-specific framework organized around five declarations that should accompany any ocular age estimate. The first is the proximal source: which biological material or signal the estimate derives from, whether a two-dimensional fundus image, a three-dimensional OCT scan, tear fluid or aqueous humor proteomics, or systemic omics that only indirectly reflect the eye. The second is the development target: what the model was actually trained to predict, which may be chronological age, a clinical outcome, or some composite index. The third is the reported quantity: whether the output is an absolute age, a residual difference from chronological age, an age-adjusted deviation, or a risk score. The fourth is the evidence design: whether the supporting study was cross-sectional, longitudinal, or interventional. The fifth is the intended use: whether the estimate is meant for mechanistic research, risk stratification, monitoring of an intervention, or clinical decision-making. Only when all five are stated explicitly, the review argues, can readers compare estimates across studies or translate them into practice.
Beyond these five declarations, the framework identifies several annotations that remain essential for any meaningful interpretation. Laterality matters, because the two eyes of one person are correlated and statistical approaches that treat eyes as independent observations inflate certainty; ophthalmology has long wrestled with this people-and-eyes problem. The reference population matters, because a model trained on one demographic or ethnic group may not calibrate to another. Disease and treatment context matters, since conditions such as diabetes, glaucoma, and age-related macular degeneration, and treatments such as intravitreal injections, alter the very features the models read. The technical version of the model matters, because updated algorithms can shift outputs without any biological change in the patient. And uncertainty in the stated output matters, because a single point estimate in years carries no information about its own reliability.
Perhaps the most consequential distinction the review draws is between a cross-sectional residual and a longitudinal aging rate. When a model estimates that a 60-year-old’s retina looks like that of a typical 66-year-old, the resulting six-year gap is a cross-sectional residual: a snapshot comparison against a reference population at one moment in time. It does not follow that the person is aging six years faster than everyone else. Repeated application of a cross-sectional model to the same individual over time does not establish an individual aging rate, because the model was never designed or validated to track change within a person. Longitudinal claims require repeated measurements evaluated against a longitudinal reference, and the observed change must be distinguishable from measurement variability. The review points to reference change values, a concept from clinical chemistry, as the appropriate tool for deciding whether a difference between two measurements on the same person exceeds the noise inherent in the method.
This confusion between cross-sectional and longitudinal inference is not unique to the eye. The brain-age literature, which pioneered the estimation of biological age from magnetic resonance imaging, has documented similar pitfalls, including regression dilution and the statistical traps that arise when age gaps are used as predictors of outcomes. The review imports lessons from that field, along with normative-modeling approaches that conceptualize disease as a deviation from expected trajectories rather than a categorical state. It also draws on the formal biomarker validation literature, including the framework that distinguishes discovery, analytical validation, clinical validation, and clinical utility, and on criteria for surrogate endpoints that specify when a biomarker can stand in for a clinical outcome in trials. By these standards, most ocular age estimates today sit firmly at the discovery stage.
The review further insists that visual-aging claims need validation against function, not just against images. The visual system offers psychophysical and performance-based measures, such as contrast sensitivity, rod-mediated dark adaptation, and hazard detection in night-driving simulators, as well as patient-reported outcomes. Delayed dark adaptation, for example, has been established as a functional biomarker for incident early age-related macular degeneration, and natural-history studies are now charting how visual function changes over years in normal aging and in early disease. An ocular age estimate that correlates with none of these functional measures risks being a statistical artifact rather than a biological signal. Differences across measurement domains, whether between an imaging-based clock and a proteomic one, must be assessed both against measurement error and against the distribution expected in the reference population, so that a difference is not declared meaningful simply because it is statistically detectable.
Even when a persistent difference survives these scrutiny layers, the review counsels restraint in interpretation. A residual age gap may support a candidate biological pattern only after technical explanations, such as image quality, camera differences, and algorithm version, and clinical explanations, such as occult disease and medication effects, have been evaluated and excluded. Only then does the gap become a hypothesis about retinal aging that can be tested in appropriate designs. Prognostic claims, in turn, require separate prospective evidence demonstrating that the estimate predicts outcomes in new samples, and clinical claims require decision-level evidence showing that acting on the estimate improves patient-relevant results. Tools such as decision curve analysis, which quantifies the net benefit of acting on a prediction at various threshold probabilities, and reporting standards such as TRIPOD+AI and its risk-of-bias companion PROBAST+AI, provide the methodological scaffolding for this progression from prediction to practice.
The practical upshot for clinicians, researchers, and the growing consumer market for biological-age tests is a checklist of questions to ask before taking an ocular age number at face value. What tissue or signal was measured? What was the model trained to predict, and against what reference population? Is the reported quantity an absolute age, a residual, or a calibrated deviation, and what is its uncertainty? Was the supporting evidence cross-sectional or longitudinal, and if longitudinal, was the change larger than measurement noise? Has the estimate been validated against visual function or patient-reported outcomes? And has any study shown that using the estimate changes decisions in ways that help patients? Until these questions are answered, the review concludes, a cross-sectional age residual should not be mistaken for an aging rate, a prognostic marker, or a clinically actionable test. The eye may indeed hold a clock, but reading it responsibly requires knowing what kind of clock it is, what it was built to measure, and what evidence stands behind each tick.
Subject of Research: Interpretation and validation of biological age estimates derived from ocular imaging and biomarkers
Article Title: Interpreting ocular age estimates: source, output, evidence, and clinical meaning
Article References: Bair, H. (2026). Interpreting ocular age estimates: source, output, evidence, and clinical meaning. Biogerontology, 27(5), Article 175. https://doi.org/10.1007/s10522-026-10525-x
Image Credits: AI Generated
DOI: 10.1007/s10522-026-10525-x
Keywords: biological age, ocular aging, retinal imaging, fundus photography, optical coherence tomography, biomarkers, deep learning, prediction models, longitudinal studies, visual function, biogerontology, clinical validation
News Source: Blake Davidson. (October 11, 2026). Your Eyes May Reveal a Biological Age, But What Does That Number Really Mean? Scienmag.
